Published : 23 Feb 2023
A Canada-US-Hongkong based biotech has appointed Aagami to support their investment and partnering needs for their ‘Single (monovalent) vaccine for targeting the four main bacterial pathogens Salmonella, ETEC / E. coli, Campylobacter & Shigella.
These 4 pathogens are responsible for the huge problem of Bacterial Dysentery affecting Hundreds of millions of cases globally per annum and Billions of Dollars in Economic Burden.
Our client’s Solution : A cost effective break-through Vaccine, addressing a High Global Unmet Need
· 1 vaccine with 2 highly conserved antigens targeting all 4 Pathogens effectively.
· These 4 pathogens are identified as Critical, High and Medium Priorities on the WHO Global Priority list of antibiotic resistant bacteria.
· Almost no competition. Saves Suffering and Lives
· Utilizes one of the “holy grails” of vaccinology.
· Cross-protective, Including against emerging variants.
· Different business models and pricing to suit all income classifications including flexible pricing for low-income (high impact) and high-income regions (High ROI).
· High ROI Investment Opportunity with High Impact.
· Blockbuster Potential. Revenue projections - $1Billion+
The Ask: Seeking Strategic Investment/Partnership
If you would like to know more about this opportunity, please contact us.